drugset / Trial / NCT06457074

Summary

Using spironolactone as the control, to assess the efficacy and safety of finerenone in patients with primary aldosteronism(PA).

Timeline

Start
2024-06-04
Primary completion
2026-04-20
Completion
2026-04-20

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Finerenone Small molecule 20 mg Oral
Comparator Spironolactone Small molecule 20 mg Oral

Indications